Costs of adjuvant breast cancer treatments.

Keywords

Medicine, Breast cancer, Oncology, Cancer, Internal medicine

References

• The burden of illness of cancer: economic cost and quality of life.Elizabeth Moignard — 2001
• Family and out-of-pocket costs for women with breast cancer.Barbara Given, Charles W. Given, M. Stommel — 1994
• The cost burden of trastuzumab and bevacizumab monoclonal antibody therapy in solid tumors: Can we afford it?Arik Drucker, Kiran Virik, Chris Skedgel — 2006
• Financial considerations in the use of adjuvant chemotherapy.Rebecca Irvin, John G. Kuhn — 1992
• National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.Patricia J. Eifel, Jan Axelson, Janitha Costa — 2001
• Adjuvant therapy of breast cancer.Charles L. Shapiro, I. Craig Henderson — 1994
• The financial burden of cancer: estimates from a study of insured women with breast cancer.Ahsan M. Arozullah, Elizabeth A. Calhoun, Michael Wolf — 2004
• Cost-effectiveness in health and medicineM. Gold — 2016
• Economic evaluations of systemic adjuvant breast cancer treatments: methodological issues and a critical review.P vanEnckevort — 1999
• Tamoxifen for early breast cancer: an overview of the randomised trialsEarly Breast Cancer Tr.group, -, Klijn, Jan — 1998
• National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision‐makingA. Brown, Kenneth Brummel‐Smith, Lavola Burgess — 1988
• A model of chemotherapy in node-negative breast cancer.Hillner Be, Thomas J. Smith — 1992
• The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.Thomas J. Smith, Bruce E. Hillner — 1993
• Breast cancer patients' out-of-pocket expenses.Kate Moore — 1999
• Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package.Herman E. Kattlove, Alessandro Liberati, Emmett B. Keeler — 1995
• Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in Breast Cancer: Is it Cost-effective?Jan Norum — 2000
• The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis.Nelson S. Hartunian, Charles N. Smart, Mark S. Thompson — 1980
• The excess costs of breast cancer health care in Hispanic and non-Hispanic female members of a managed care organizationKristine Tollestrup, Floyd J. Frost, Christine A. Stidley — 2001
• Adjuvant therapy for breast cancer: practice patterns of community physicians.Linda C. Harlan, Jeffrey S. Abrams, Joan L. Warren — 2002
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.Mary E. Charlson, Peter Pompei, Kathy L. Aleš — 1987

Cited by

No citing papers recorded for this paper.

Related papers

• Research progress of aluminum adjuvantChen Ting-tin — 2015
• Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine VaccineZongmin Zhao, Yun Hu, Theresa Harmon — 2019
• Immune Adjuvant Effect of CFNCpG Motif on Antigen of Inactivated BVDV1Miao Li-guang — 2008
• Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvantYan Cao, Xiaoyue Zhu, Md. Nazir Hossen — 2018
• Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinomaE. C. Holmes — 1994
• The Role of Serum CEA as a Prognostic Indicator in Stage II and III Breast Cancer Patients Treated With Adjuvant ChemotherapyRichard L. Theriault, Gabriel N. Hortobágyi, Herbert A. Fritsche — 1989